CONFIDENTIALITY AND EXCHANGE OF INFORMATION. Confidentiality and the Exchange of Confidential Information shall be governed by Article 8 of the License Agreement.
CONFIDENTIALITY AND EXCHANGE OF INFORMATION. 15.1. Viainvest complies with the confidentiality requirements in accordance with the legal enactments of the Republic of Latvia and the European Union. Viainvest may disclose information on any transaction, Financial Instrument Accounts and on other matters related to the Investor’s activities on the Platform only to the Investor and/or the Investor’s Representatives, using the contact information provided by the Investor. Viainvest may disclose such information to Third Parties with or without the consent of the Investor, if it is required by the legislation of the Republic of Latvia and/or the European Union.
15.2. Viainvest will disclose information about the transaction, the Investor, the Investor’s Representatives, the Investor’s beneficial owners, if it is required by law and at the request of the competent state authorities.
CONFIDENTIALITY AND EXCHANGE OF INFORMATION. 8.1 For the duration of this AGREEMENT, each Party undertakes to notify the other Party promptly of any information they may obtain or develop relating to the harmlessness and/or usefulness of any LICENSED PRODUCT in particular any information regarding any serious effect which one can reasonably believe is linked to the use of the LICENSED PRODUCT.
8.2 For the duration of this AGREEMENT plus a period of five years and regardless of it being terminated prematurely, the Parties cannot disclose, directly or indirectly, any confidential information received by the other Party within the framework of this AGREEMENT or its preparation, without prior consent of the other Party. The information are deemed confidential if they are disclosed: • in any written form (on paper or electronically) and clearly designated as being confidential; or • in verbal form, insofar as its confidentiality is confirmed in writing within 30 calendar days; or • in the form of samples, specimens or other biological materials that are formally designated as being confidential at the latest 30 days after they have been supplied. The Parties are only authorized to disclose confidential information if it is directly and strictly necessary: a) to the development and use of the LICENSED PRODUCTS or the LICENSED PROCESS; b) to obtain administrative authorizations for use; c) in order to comply with and respond to the requirements of the governmental authorities. In such an instance, the Parties must take reasonable measures to ensure that any unauthorized use or disclosure shall be carried out by individuals to whom the confidential information will be entrusted and specifically drawing their attention to the confidential nature of this information. With regards to its own staff, each Party shall only be authorized to entrust the said information to members linked to them by a confidentiality obligation that is at least equivalent to the effects of the confidentiality obligation set out in this Article. The confidentiality obligation in this Article shall not apply to information a) that is or becomes accessible to the public, or b) that is already in the possession of the recipient Party at the time it is entrusted to them by the other Party, the onus being on them to provide proof of this or c) which shall subsequently, excluding any contractual breach, be entrusted to the recipient Party by a THIRD PARTY not belonging to the public authority, the onus being on the recipient party to provid...
CONFIDENTIALITY AND EXCHANGE OF INFORMATION. 15.1. Viainvest complies with the confidentiality requirements in accordance with the legal enactments of the Republic of Latvia and the European Union. Viainvest may disclose information on any transaction, Financial Instrument Accounts and on other matters related to the Customer activities on the Platform only to the Customer and/or the Customer’s Representatives, using the contact information provided by the Customer. Viainvest may disclose such information to Third Parties with or without the consent of the Customer, if it is required by the legislation of the Republic of Latvia and/or the European Union.
15.2. Viainvest will disclose information about the transaction, the Customer, the Customer’s Representatives, the Customer’s beneficial owners, if it is required by the regulatory enactments and at the request of the competent state authorities.
CONFIDENTIALITY AND EXCHANGE OF INFORMATION. 8.1 For the duration of this AGREEMENT, each Party undertakes to notify the other Party promptly of any information they may obtain or develop relating to the harmlessness and/or usefulness of any LICENSED PRODUCT in particular any information regarding any serious effect which one can reasonably believe is linked to the use of the LICENSED PRODUCT.
8.2 For the duration of this AGREEMENT plus a period of five years and regardless of it being terminated prematurely, the Parties cannot disclose, directly or indirectly, any confidential information received by the other Party within the framework of this AGREEMENT or its preparation, without prior consent of the other Party. The information are deemed confidential if they are disclosed: • in any written form (on paper or electronically) and clearly designated as being confidential; or • in verbal form, insofar as its confidentiality is confirmed in writing within 30 calendar days; or • in the form of samples, specimens or other biological materials that are formally designated as being confidential at the latest 30 days after they have been supplied. The Parties are only authorized to disclose confidential information if it is directly and strictly necessary: a) to the development and use of the LICENSED PRODUCTS or the LICENSED PROCESS; b) to obtain administrative authorizations for use; c) in order to comply with and respond to the requirements of the governmental authorities.
CONFIDENTIALITY AND EXCHANGE OF INFORMATION. 15.1. Decamel complies with confidentiality requirements in accordance with the regulations of the Republic of Estonia and the European Union. Decamel may disclose information regarding any transaction, the Private Account of the User (User Cabinet on the Platform) and any other matters related to the User’s activities on the Platform only directly to the User and/or the User’s representatives via the User’s contact information provided under the Agreement. Decamel may disclose such information to third parties with the User’s consent or without consent if required by the regulations of the Republic of Estonia and/or the European Union, the court decision and/or as required by the Estonian law.
15.2. Decamel will disclose information about any transaction, the User and/or the User’s representatives, User’s beneficial owners upon official request of authorized public authorities. The prohibition of non-disclosure of information shall not apply to cases when such information is disclosed to the competent state institutions, regulators and officials upon their justified request in the cases and in accordance with the procedures specified in regulatory enactments, including decision of a court and/or other decisions of the regulatory system to which the Platform is obliged to adhere by law.
15.3. If required by regulation, Decamel will collect, process and provide data and information on the Investor, the User’s representatives, the User’s beneficial owners and any transaction of the User to tax authorities of one or more countries. Decamel provides information to the State Revenue Service of the Republic of Estonia which automatically sends information to the tax authority in the country of residence of the User if such country participates in exchange of information.
15.4. Unless prohibited by the applicable regulation, Decamel may notify the User on the contents of information related to the User submitted to the State Revenue Service of the Republic of Estonia.
15.5. Decamel may share any information submitted by the User (i) with any company consolidated and/or affiliated with Decamel, (ii) any company which is involved in the provision of services on the Platform and/or (iii) as in any case provided in Decamel Privacy Rules.
15.6. Additionally to the above, the confidentiality disclaimers apply as specified on the Platform and available here xxxxx://xxxxxxx.xxx/en/security/confidentiality-disclaimers.
CONFIDENTIALITY AND EXCHANGE OF INFORMATION. 8.1 For the duration of this AGREEMENT, each Party undertakes to notify the other Party promptly of any information they may obtain or develop relating to the harmlessness and/or usefulness of any LICENSED PRODUCT in particular any information regarding any serious effect which one can reasonably believe is linked to the use of the LICENSED PRODUCT.
CONFIDENTIALITY AND EXCHANGE OF INFORMATION. Xxxxxx Xxxxxxxx Ltd will keep confidential information securely and within the principles of Data Protection legislation. It is agreed that the need to share information to manage risk of harm to others and risk of self harm will override the basic principle of confidentiality. Specifically Xxxxxx Xxxxxxxx Ltd will disclose information to LRPT where there is a risk of (or act of) serious self harm, harm to others or criminal activity. Any serious concern regarding a risk of (or act of) serious self harm, harm to others or criminal activity will be reported to the Director of Human Resources on the same day. Invoices will be submitted monthly, detailing the sessions offered and delivered and showing those that were cancelled at short notice and those where the service user did not arrive. Service review meetings will be held with Xxxxxx Xxxxxxxx Ltd quarterly to maintain relationships, consider monitoring information, and highlight any difficulties and operational issues. These meetings may be more frequent during the implementation phase of the contract. Review meetings will identify and agree any actions necessary on either side to achieve changes or improvements to the service. Monitoring will include: Number of ongoing service users Number of new referrals Number of one to one sessions held Number of service users completing their involvement with the service, with reasons Number of cancellations by Xxxxxx Xxxxxxxx Ltd Number of DNA s and cancellations by staff with under 48 hours notice Annual review meetings will include an overview of the service for the previous twelve months, together with quality assessments and an evaluation of the outcomes of the service for the individuals receiving the service. Xxxxxx Xxxxxxxx Ltd will submit an annual report demonstrating evidence of, and commitment to, provision of a quality service that continues to meet the changing needs of the Trust. Meetings will include: For LRPT - Director Human Resources and others as relevant For Xxxxxx Xxxxxxxx Ltd – Xx Xxxxxx Xxxxxxxx and others as relevant Xxxxxx Xxxxxxxx Ltd will ensure that contingency plans are in place for any risks to business and service provision processes. These plans will address any risks identified in order to protect and ensure continuity of the services and operational delivery. Plans will be reviewed annually. Xxxxxx Xxxxxxxx Ltd will advise the Director of Human Resources of the clinical supervisors’ absence i.e. annual leave, sickness and training...
CONFIDENTIALITY AND EXCHANGE OF INFORMATION. 8.1 For the duration of this AGREEMENT, each Party undertakes to notify the other Party promptly of any information they may obtain or develop relating to the harmlessness and/or usefulness of any LICENSED PRODUCT in particular any information regarding any serious effect which one can reasonably believe is linked to the use of the LICENSED PRODUCT.
8.2 For the duration of this AGREEMENT plus a period of five years and regardless of it being terminated prematurely, the Parties cannot disclose, directly or indirectly, any confidential information received by the other Party within the framework of this AGREEMENT or its preparation, without prior consent of the other Party. The information are deemed confidential if they are disclosed: • in any written form (on paper or electronically) and clearly designated as being confidential; or • in verbal form, insofar as its confidentiality is confirmed in writing within 30 calendar days; or • in the form of samples, specimens or other biological materials that are formally designated as being confidential at the latest 30 days after they have been supplied.
CONFIDENTIALITY AND EXCHANGE OF INFORMATION
